<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693251</url>
  </required_header>
  <id_info>
    <org_study_id>2007-0714</org_study_id>
    <nct_id>NCT00693251</nct_id>
  </id_info>
  <brief_title>Optimal Stenting Strategy For True Bifurcation Lesions</brief_title>
  <acronym>PERFECT</acronym>
  <official_title>Phase IV Study of Optimal Stenting Strategy For True Bifurcation Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is unclear which stenting strategy will be optimal for true bifurcation coronary lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The outcome of percutaneous coronary intervention of bifurcation lesions with bare-metal&#xD;
      stents is hindered by increased rates of procedural complications and long-term major adverse&#xD;
      cardiac events compared with non-bifurcated lesions.1 Randomized studies have demonstrated&#xD;
      that drug-eluting stents reduce restenosis when used in relatively simple lesions; and recent&#xD;
      data have demonstrated efficacy of the sirolimus-eluting stent for bifurcation lesions&#xD;
      compared with historical data of BMS. In one study of bifurcation lesions, the overall&#xD;
      restenosis rate was 23%, with the majority of side branch restenoses occurring at the ostium&#xD;
      after use of a T-stenting technique. Indeed, side branch restenosis occurred in 16.7% after&#xD;
      T-stenting, compared with 7.1% after other stenting techniques.&#xD;
&#xD;
      The &quot;crush&quot; technique of bifurcation stenting with DESs was introduced by Colombo et al. in&#xD;
      2003 as a relatively simple technique that ensures complete coverage of the side branch&#xD;
      ostium, thereby facilitating drug delivery at this site. Initial data of 20 patients treated&#xD;
      with this technique with SES suggest that it is a safe method, with an acceptable rate of&#xD;
      procedural complications and no further adverse events up to 30 days follow-up. Recently,&#xD;
      angiographic data have shown the importance of simultaneous kissing balloon post-dilation in&#xD;
      reducing restenosis and need for target lesion revascularization. They also reported that&#xD;
      compared to T-stenting, crushing with final kissing balloon dilatation was associated with&#xD;
      lower rate of restenosis and target lesion revascularization. Consequently, the crushing is&#xD;
      currently most promising technique in treating bifurcation lesions using two stents. However,&#xD;
      despite the advance of bifurcation stenting technique, the superiority of bifurcation&#xD;
      stenting with crushing technique over simple stenting in bifurcation lesion has not been&#xD;
      demonstrated.&#xD;
&#xD;
      Therefore, we conducted the prospective randomized study comparing crushing technique with&#xD;
      final kissing balloon dilatation and a simple technique (main vessel stenting and provisional&#xD;
      T-stenting) for treatment of true bifurcation lesions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic binary restenosis rate (diameter stenosis &gt;= 50%) at 8 months in either main or side branch</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of major cardiac adverse events (MACE) including death, MI, stent thrombosis and ischemia-driven target vessel revascularization</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reocclusion rate at the side branch at 8 month angiographic follow-up</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late loss at the main vessel and the side branch</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restenosis rate at the main vessel and/or side branch</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of bifurcation angle</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of new three segment bifurcation QCA software</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopic time</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of contrast agent</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of used stents</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FFR assessment in the side branch</measure>
    <time_frame>baseline and 8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>bifurcation stent technique</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>crush technique</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bifurcation stent techniqe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>provisional T stenting</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Crush technique</intervention_name>
    <description>Crush technique</description>
    <arm_group_label>bifurcation stent technique</arm_group_label>
    <other_name>Sirolimus, Paclitaxel, Zotarolimus and Everolimus stents</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>provisional T stenting</intervention_name>
    <description>Provisional T stenting</description>
    <arm_group_label>bifurcation stent techniqe</arm_group_label>
    <other_name>Sirolimus, Paclitaxel, Zotarolimus and Everolimus stents</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical&#xD;
&#xD;
               -  Patients with angina and documented ischemia or patients with documented silent&#xD;
                  ischemia&#xD;
&#xD;
               -  Patients who are eligible for intracoronary stenting&#xD;
&#xD;
               -  Age &gt;18 years, &lt;75 ages&#xD;
&#xD;
          -  Angiographic&#xD;
&#xD;
               -  De novo lesion located in a major bifurcation point with the MEDINA&#xD;
                  classification type 1.1.0, 1.0.0, or 0.1.0&#xD;
&#xD;
               -  Main vessel : &gt;= 2.5 mm in vessel size, &gt;= 50% in diameter stenosis and =&lt; 50 mm&#xD;
                  in lesion length by visual estimation, in which the lesion seems to be covered&#xD;
                  with =&lt; 2 stents&#xD;
&#xD;
               -  Side branch : &gt;= 2.0 mm in vessel size, &gt;= 50% in diameter stenosis, and &lt; 20 mm&#xD;
                  in lesion length by visual estimation, in which the lesion seems to be covered&#xD;
                  with single stent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Known hypersensitivity or contra-indication to contrast agent, heparin, sirolimus and&#xD;
             paclitaxel&#xD;
&#xD;
          -  Limited life-expectancy (less than 1 year) due to combined serious disease&#xD;
&#xD;
          -  ST-elevation acute myocardial infarction &lt; 2 weeks&#xD;
&#xD;
          -  Characteristics of lesion:&#xD;
&#xD;
               -  Left main disease&#xD;
&#xD;
               -  In-stent restenosis&#xD;
&#xD;
               -  Graft vessels&#xD;
&#xD;
               -  Chronic total occlusion&#xD;
&#xD;
               -  TIMI flow =&lt; grade 2 in the side branch&#xD;
&#xD;
          -  Renal dysfunction, creatinine &gt;= 2.0mg/dL&#xD;
&#xD;
          -  Contraindication to aspirin, clopidogrel or cilostazol&#xD;
&#xD;
          -  LV ejection fraction =&lt; 35%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Jung Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Busan Saint Mary's Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheongju Saint Mary's Hospital</name>
      <address>
        <city>Cheongju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangwon University Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungsang University Hospital</name>
      <address>
        <city>Jinju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>PyeongChon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University, Kangnam St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Veterans Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aju University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>June 5, 2008</study_first_submitted>
  <study_first_submitted_qc>June 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2008</study_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CardioVascular Research Foundation, Korea</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>MD,PhD, Chairman,Heart Institute, Asan Medical Center,University of Ulsan,College of Medicine</investigator_title>
  </responsible_party>
  <keyword>stent</keyword>
  <keyword>bifurcation</keyword>
  <keyword>coronary artery stenosis</keyword>
  <keyword>balloon angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

